Weight Loss Drugs: Can New Firms Take Market Share …

Obesity Drug Industry: The Next Wave of GLP-1 Competition2 Companies Poised to Capitalize on the Rise of GLP-1 Drugs

$100
OFF

The Weight-Loss Battle That Could Rattle Eli Lilly's $100 Billion …

3 weeks from now

Dec 5, 2024 · An age-old battle in pharmaceuticals could further rattle Eli Lilly stock and its potential $100 billion market in weight-loss drugs. The showdown centers on compounders, …

investors.com

$200
OFF

Can New GLP-1 Contenders Disrupt The Weight-Loss Giants, Lilly …

3 weeks from now

Oct 3, 2024 · New public and private entrants are emerging to challenge the leading positions of Novo Nordisk (NVO) and Eli Lilly (LLY) in the GLP-1 market. This potential $200 billion market …

geneonline.com

$70
OFF

New Drugs From Public And Private Companies Will Challenge …

3 weeks from now

success revitalizes drug development. We expect 16 new obesity drugs could launch by 2029, with roughly $70 billion of the GLP-1 market coming from these new challengers by 2031. Key …

contentstack.io

$44
OFF

Battle Over Weight-Loss Drugs: Follow IBD's Coverage| Investor's ...

3 weeks from now

Dec 20, 2024 · The two leading weight-loss drugs today are Wegovy from Novo Nordisk and Zepbound from Eli Lilly. Together, they are expected to generate about $44.6 billion in sales in …

investors.com

$200
OFF

2 Companies Poised To Capitalize On The Rise Of GLP-1 Drugs

3 weeks from now

Jan 21, 2025 · GLP-1 Drugs: Demand Surges in a Long-Established Market The market for GLP-1 drugs is projected to exceed $200 billion in annual sales by 2031, according to Morningstar …

morningstar.com

$150
OFF

Weight-loss Drug Developers Line Up To Tap Market Worth $150 …

3 weeks from now

May 12, 2023 · Novo Nordisk's Wegovy and Eli Lilly's Zepbound are so far the leaders in the weight-loss drug market, which is estimated to be worth about $150 billion by the early 2030s.

reuters.com

$100
OFF

This 1 Number May Ensure Eli Lilly's Dominance In The Weight …

3 weeks from now

Apr 8, 2024 · Eli Lilly's (NYSE: LLY) shares have soared over the past year as the company grew its presence in what could become a $100 billion drug market. The company sells two drugs …

nasdaq.com

200%
OFF

This Weight-Loss Drug Stock Could Gain 200%, Challenge Novo …

3 weeks from now

Novo Nordisk and Eli Lilly weight-loss drugs Wegovy and Zepbound are currently dominating the obesity market, but Jefferies analysts see one biotech as particularly well suited to challenge …

barrons.com

67%
OFF

Eli Lilly Stock Tumbles On Slower-Than-Expected Weight Loss Drug …

3 weeks from now

Jan 18, 2025 · GLP-1 drugs have become all the rage for weight loss, with sales for drugs like Novo Nordisk's Ozempic and Eli Lilly's (LLY 1.67%) Mounjaro skyrocketing over the past year. …

fool.com

17%
OFF

The Next Ozempic: Inside The New Weight Loss Drug Competition

3 weeks from now

Jan 21, 2025 · Eli Lilly: The American multinational is also developing a stronger weight-loss injection, retatrutide, which, in a small clinical trial, helped patients lose 17% of their weight in …

qz.com

$1
OFF

Weight-Loss Drugs Could Make Eli Lilly The First $1 Trillion Pharma ...

3 weeks from now

Eli Lilly stock could keep climbing thanks to strong demand for Mounjaro and Zepbound weight-loss drugs. A $1 trillion market cap could be in the pharma company’s future.

barrons.com

35%
OFF

Novo Nordisk And Eli Lilly Rival Soars 35% After Promising Weight …

3 weeks from now

Feb 26, 2024 · Zealand Pharma's Phase 2 trial was an "uniquivocal win" for a drug that can treat both liver disease and obesity, analysts said.

cnbc.com

$2
OFF

Eli Lilly Tumbles On Lowered Guidance As Weight-Loss Drug Sales …

3 weeks from now

Jan 14, 2025 · The race to develop new weight-loss drugs has been heating up. LLY Stock Technical Ratings Earlier this week, Eli Lilly said it would spend $2.5 billion to acquire a cancer …

investors.com

$724
OFF

Eli Lilly's SWOT Analysis: Stock Soars On GLP-1 Success, Faces ... - MSN

3 weeks from now

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been making waves in the healthcare sector with its groundbreaking …

msn.com

FAQs about Weight Loss Drugs: Can New Firms Take Market Share … Coupon?

Who dominates the weight-loss drug market?

In the obesity drug landscape, GLP-1 agonists from Novo Nordisk and Eli Lilly dominate, together accounting for 68% of weight-loss drug sales. However, new players are gearing up to challenge their dominance. ...

Which drug brands dominate the weight-loss market in 2031?

Due to their first-mover advantages and innovation with next-generation products, Novo and Lilly are expected to retain nearly 70% of the total market by 2031. In the obesity drug landscape, GLP-1 agonists from Novo Nordisk and Eli Lilly dominate, together accounting for 68% of weight-loss drug sales. ...

How many new obesity drugs will come out by 2029?

We expect 16 new obesity drugs could launch by 2029, with roughly $70 billion of the GLP-1 market coming from these challengers by 2031. That said, Novo and Lilly are also advancing their next-generation pipelines, beginning with Novo’s cagrisema and Lilly’s orforglipron in 2026. ...

Will new public and private companies disrupt Eli Lilly & Novo Nordisk's dominance?

New public and private companies are poised to disrupt Eli Lilly and Novo Nordisk's dominance in the obesity drug market with GLP-1 innovations. New public and private entrants are emerging to challenge the leading positions of Novo Nordisk (NVO) and Eli Lilly (LLY) in the GLP-1 market. ...

Could a battle in pharmaceuticals Rattle Eli Lilly stock?

An age-old battle in pharmaceuticals could further rattle Eli Lilly (LLY) stock and its potential $100 billion market in weight-loss drugs. The showdown centers on compounders, companies allowed to create knockoffs of drugs to offset shortages. ...

Are food companies planning a future with weight-loss drugs?

Food giants such as Nestlé are already planning for a future where the drugs dampen demand for sugary snacks. Bosses of consumer-goods firms brought up weight-loss drugs twice as often in the last full set of quarterly earnings calls, in late 2023, as they had in the previous one (see chart 1). ...